What Is Polyarteritis Nodosa?

Polyarteritis nodosa is a rare, systemic necrotizing vasculitis that targets medium-sized and small muscular arteries. The name itself is descriptive: "poly" for the many arteries involved, "arteritis" for the arterial inflammation, and "nodosa" for the small nodules – the microaneurysms – that form along inflamed vessels. What sets PAN apart from many other vasculitides is the caliber of vessel it attacks. It does not primarily inflame the tiniest capillaries, arterioles, and venules; instead it concentrates its damage on the muscular arteries that supply organs, which is exactly why its complications – kidney infarction, bowel ischemia, nerve damage – reflect the loss of blood supply to whole territories of tissue.

PAN is a focal and segmental disease, meaning it does not inflame an entire artery uniformly but strikes patchy segments, often at branch points where blood flow creates turbulence. Inflamed segments undergo fibrinoid necrosis of the vessel wall, the structural failure that produces both aneurysms (where the weakened wall balloons outward) and stenoses or occlusions (where inflammation and clot narrow or block the lumen). Because different organs are supplied by different arteries, PAN can present in strikingly varied ways – with kidney involvement, abdominal pain, skin nodules, testicular pain, or the dramatic nerve syndrome called mononeuritis multiplex.

A defining feature of classic PAN is that it is typically ANCA-negative. Anti-neutrophil cytoplasmic antibodies (ANCA) are the hallmark of a different family of small-vessel vasculitides (such as granulomatosis with polyangiitis or microscopic polyangiitis). Their absence in PAN is an important diagnostic clue and a reminder that PAN sits in its own category – an immune-complex and medium-vessel disease rather than an ANCA-driven small-vessel one. Historically, a substantial share of cases – on the order of 30% – were associated with chronic hepatitis B virus infection, a connection so important it shapes treatment.

The Vasculitis Classification: Small, Medium & Large Vessel

Understanding where polyarteritis nodosa fits requires a map of the vasculitides, which are grouped largely by the size of the blood vessel they predominantly attack. This classification (formalized in the Chapel Hill Consensus Conference framework) is not academic trivia – it predicts the clinical picture, the antibody profile, and the treatment. PAN sits squarely in the medium-vessel category.

The practical value of this map is that it tells clinicians what to look for. Because PAN is a medium-vessel disease, it does not typically cause the glomerulonephritis that defines small-vessel renal disease; instead it causes renal artery involvement with hypertension and kidney infarction. Because it spares the smallest vessels, it generally does not cause pulmonary capillaritis or alveolar hemorrhage. And because it is immune-complex rather than ANCA-driven, it is typically ANCA-negative. Each of these distinctions flows directly from the vessel-size category, which is why this classification is the backbone of how vasculitis is diagnosed and treated.

Pathophysiology: Fibrinoid Necrosis & Immune Complexes

The microscopic signature of PAN is fibrinoid necrosis of the arterial wall. When an artery is attacked, inflammatory cells infiltrate the wall, plasma proteins (including fibrin) leak into the damaged tissue, and the normal architecture of the vessel is destroyed and replaced by a smudgy, eosinophilic, "fibrin-like" material on histology – hence "fibrinoid." This necrosis is transmural, meaning it involves the full thickness of the artery wall, which is what makes PAN so destructive: the wall loses its structural integrity, predisposing to both aneurysm formation and thrombotic occlusion.

A second hallmark is that lesions exist at different stages simultaneously. In the same patient, one can find acute lesions with active inflammation and fibrinoid necrosis alongside healing or healed lesions with fibrosis and scarring. This temporal heterogeneity reflects the focal, recurrent nature of the disease and is itself a diagnostic clue distinguishing PAN from conditions that produce uniform, single-stage lesions.

The driving mechanism in a large share of cases is immune complex deposition. Circulating immune complexes – antigen bound to antibody – lodge in the walls of medium arteries, particularly at the branch points where turbulent flow favors deposition. There they activate the complement system, generating chemoattractants (like C5a) that summon neutrophils. The recruited neutrophils release reactive oxygen species and proteolytic enzymes, including matrix metalloproteinases, which digest the vessel wall and produce the fibrinoid necrosis. This is why PAN is considered, in its HBV-associated form especially, a type III (immune-complex) hypersensitivity vasculitis.

Organ Involvement: Renal, Mesenteric, Hepatic & Nerves

Because PAN attacks the muscular arteries that feed organs, its clinical picture is essentially a map of which arteries are inflamed. Several territories are characteristically involved.

The renal arteries are among the most commonly affected. PAN does not typically cause glomerulonephritis (that is a small-vessel phenomenon); instead it inflames the medium renal arteries, producing renal infarction, renin-driven hypertension (often severe), and microaneurysms visible on renal angiography. Renal involvement is a major driver of morbidity and was historically a leading cause of death in untreated disease.

The mesenteric arteries supply the gut, and their involvement produces one of PAN's most feared complications: intestinal angina (abdominal pain after eating, from inadequate blood flow) that can progress to bowel ischemia, infarction, perforation, or hemorrhage. Abdominal involvement is a medical emergency. The hepatic arteries can likewise be affected, producing hepatic microaneurysms and, in HBV-associated disease, overlapping with the liver pathology of the virus itself.

Perhaps the most distinctive feature is mononeuritis multiplex: PAN inflames the small arteries (the vasa nervorum) that supply peripheral nerves, causing infarction of individual nerves. The result is a patchwork of asymmetric motor and sensory deficits – a wrist drop here, a foot drop there, numbness in a discrete nerve distribution – rather than the symmetric "glove and stocking" pattern of typical neuropathy. Mononeuritis multiplex is so characteristic of medium-vessel vasculitis that its presence strongly suggests PAN. Skin (livedo reticularis, tender nodules, ulcers) and the testes (orchitis causing testicular pain) are other classic targets.

Microaneurysms, Angiography & Diagnosis

One of the most visually striking and diagnostically useful features of PAN is the microaneurysm. As fibrinoid necrosis weakens segments of the arterial wall, those segments balloon outward into small saccular aneurysms, typically 1 to 5 millimeters across. On catheter angiography (or CT/MR angiography) of the renal, mesenteric, or hepatic circulation, these appear as a characteristic pattern of multiple small aneurysms interspersed with areas of narrowing – a "beads on a string" or "rosary bead" appearance that is highly suggestive of PAN.

Diagnosis rests on combining this imaging with tissue biopsy (of an affected nerve, muscle, skin, or other involved organ) showing the necrotizing arteritis with fibrinoid necrosis, plus the clinical context. Laboratory testing typically shows nonspecific inflammation (elevated ESR and CRP) and, crucially, is usually ANCA-negative, which helps separate PAN from the ANCA-associated small-vessel vasculitides. Testing for hepatitis B (and increasingly hepatitis C) is essential, because identifying an HBV-associated case fundamentally changes the treatment strategy.

Sea Moss Nutrients and PAN Vascular Biology

With the mechanism mapped – immune complexes, complement, neutrophils, fibrinoid necrosis, and a weakened endothelium – here is how specific sea moss nutrients intersect with the biology, kept honest about the difference between mechanistic interest and medical effect. None of these is a treatment for vasculitis.

The HBV-PAN Connection

No discussion of polyarteritis nodosa is complete without the hepatitis B virus. Historically, roughly 30% of PAN cases were associated with chronic HBV infection, and in regions with high HBV prevalence the proportion was even higher. This is not a coincidental overlap – it is a direct mechanistic link, and it is one of the clearest examples in medicine of a virus driving a vasculitis through immune complexes.

This mechanism is why HBV-associated PAN is treated differently from non-viral PAN. The conventional approach combines antiviral therapy (to suppress the virus and shut off the antigen supply at the source) with a short course of glucocorticoids and, often, plasma exchange to physically remove circulating immune complexes – while deliberately limiting prolonged immunosuppression, which could otherwise worsen the underlying viral infection. Treating the virus treats the vasculitis. As HBV vaccination and antiviral therapy have spread, the proportion of PAN that is HBV-associated has fallen substantially, though it remains a vital consideration in every new diagnosis.

Conventional Treatment of PAN

This section exists to be crystal clear about where real treatment lives. PAN has effective, well-established medical therapy, and the strategy depends heavily on severity and on whether HBV is involved. Sea moss does not belong on this ladder; it sits beneath it as nutrition.

• Glucocorticoids (prednisone, sometimes IV methylprednisolone) are the foundation for controlling active inflammation quickly, used in nearly all forms of PAN.
• Cyclophosphamide is added for severe, organ-threatening (non-viral) disease – renal, gastrointestinal, cardiac, or neurological involvement – to induce remission, typically alongside glucocorticoids.
• For HBV-associated PAN, the strategy shifts to antiviral therapy (to suppress the virus at the source) plus a short course of glucocorticoids and frequently plasma exchange to clear immune complexes, with prolonged immunosuppression deliberately avoided.
• Maintenance immunosuppressants (such as azathioprine or methotrexate) may follow induction to sustain remission and spare steroids.
• Supportive care – aggressive blood-pressure control, treatment of complications, and surgery for bowel infarction or aneurysm rupture – is critical given the organ damage PAN can cause.

Safe Use of Sea Moss with PAN Care

If your rheumatologist is comfortable with you adding sea moss as dietary support, a few specifics deserve attention. The order of operations is firm: medical care first, food second, full disclosure throughout.

• Fucoidan and anticoagulants/antiplatelets. Fucoidan is a sulfated polysaccharide with mild blood-thinning properties in some studies. PAN patients may be on anticoagulants, antiplatelets, or facing procedures; flag sea moss to your physician so bleeding risk is accounted for.
• Iodine and thyroid monitoring. Sea moss is a potent natural source of iodine. If you have any thyroid involvement or take thyroid medication, your provider should account for it; keep TSH and free T4 monitoring on schedule and report sea moss as part of your intake.
• Hepatitis B and liver status. If your PAN is HBV-associated, your liver and antiviral care are paramount. Discuss any supplement with the team managing your hepatitis B, and never let sea moss displace antiviral dosing.
• Steroids, bone, and blood pressure. Long-term glucocorticoids accelerate bone loss, where sea moss's magnesium and trace minerals are generally supportive. PAN-related hypertension is managed medically; sea moss does not lower vasculitis-driven blood pressure and should not replace antihypertensives.
• Cyclophosphamide and immunosuppression. If you are on cyclophosphamide, azathioprine, methotrexate, or any immunosuppressant, your rheumatology team should know about every supplement you take so your monitoring stays meaningful and your care coordinated.